A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

NCT ID: NCT03251443

Last Updated: 2020-12-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 34 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-08-08
• Study Completion Date: 2019-05-08

Brief Summary

The purpose of this study is to explore the efficacy and safety of second-line treatment of apatinib in advanced intrahepatic cholangiocarcinoma patients and evaluate drug safety, progression free and overall survival. The primary endpoint of this study is objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS).

Conditions

Intrahepatic Cholangiocarcinoma; Second-line Treatment

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Apatinib

A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.

Group Type: EXPERIMENTAL

Apatinib

Intervention Type: DRUG

500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.

Interventions

Apatinib

500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.

Intervention Type: DRUG

Other Intervention Names

Apatinib mesylate tablets

Eligibility Criteria

Inclusion Criteria

• Patients with a histologic or cytologic diagnosis of intrahepatic cholangiocarcinoma with stage IV;
• Have progressed after systematic chemotherapy/target therapy, or cannot tolerated with first-line treatment;
• The previous treatment and the present trial registration must be at least 2 weeks apart, and they must have recovered from any toxicity of a previous treatment;
• Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1;
• Eastern Cooperative Oncology Group performance score (ECOG): 0-2;
• Life expectancy of at least 12 weeks;
• Subjects who understand and voluntarily signed a written informed consent form.

Exclusion Criteria

• Previous locoregional therapy within 4 weeks prior to enrollment.
• Diagnosed with hepatocellular carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular carcinoma.
• History of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma.
• Prepared for liver transplantation.
• Patients with contraindications (active bleeding, ulcers, intestinal perforation, intestinal obstruction, within 30 days after major surgery, uncontrolled high blood pressure medication, III-IV level cardiac insufficiency, severe liver and kidney dysfunction).
• A previous history of Interstitial pulmonary disease, drug-induced interstitial disease, radiation pneumonitis requiring hormonal therapy or active interstitial lung disease with any clinical evidence.
• Use of CYP3A4 inhibitor within 7 days or CYP3A4 inducer within 12 days prior to enrollment.
• Patients with central nervous system metastases or brain metastasis
• Previous definite diagnosis of neuropsychiatric disturbances, including epilepsy or dementia.
• Pregnant or lactating women.
• Patients with bone metastasis received palliative radiation within 4 weeks prior to enrollment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Peking Union Medical College Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hai-tao Zhao

Role: STUDY_CHAIR

Peking Union Medical College Hospital (PUMCH)

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

JS-1392

Identifier Type: -

Identifier Source: org_study_id